Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 6,001 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 6,001 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the transaction, the chief financial officer owned 36,355 shares of the company’s stock, valued at $3,631,864.50. The trade was a 14.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, July 6th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $122.25, for a total value of $611,250.00.
• On Monday, June 8th, Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.82, for a total value of $469,100.00.

Mirum Pharmaceuticals Stock Up 0.8%

MIRM stock opened at $98.97 on Thursday. Mirum Pharmaceuticals, Inc. has a twelve month low of $63.23 and a twelve month high of $130.00. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The firm has a market cap of $6.43 billion, a PE ratio of -6.80 and a beta of 0.52. The business has a 50 day moving average of $110.64 and a 200 day moving average of $101.97.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The company had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. During the same period last year, the firm posted ($0.12) earnings per share. The company’s revenue was up 37.9% compared to the same quarter last year. On average, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Cullen Frost Bankers Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $30,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $32,000. CIBC Private Wealth Group LLC purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $32,000. Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals during the third quarter valued at approximately $33,000. Finally, Comerica Bank lifted its position in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Robert W. Baird set a $123.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 6th. TD Cowen cut their price target on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Royal Bank Of Canada cut their price target on shares of Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, Wall Street Zen raised shares of Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $137.33.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.